|Hormonal Replacement Therapy|
|Business Reports - Market Report|
Hormonal Replacement Therapy for Menopausal Symptoms - Safety fears continue to haunt the market
Sales of hormone replacement therapies treating menopausal symptoms have seen a sharp decline in recent years as a result of safety concerns raised by the Women's Health Initiative (WHI) study in 2002. Coupling this with Pfizer's acquisition of Wyeth, the leading estrogen manufacturer, the future direction of the market is uncertain.Recovery of the HRT market following the WHI has been slow. In recent years an increase in sales in the USwhich remains the largest marketwas despite the continuous volume decrease.
Premarin remains the market leading drug accounting for over 37% of total sales in 2009 across the seven major markets. The difficulty in replicating the exact conjugated estrogen composition will continue to protect it from generic incursion for the foreseeable future.
The future of Aprela continues to be uncertain and the US Food and Drug Administration may decide not to approve the drug due to safety concerns. Nevertheless, should the drug launch Pfizer could drive market growth in an attempt to restore the multibillion market.
Newer news items
|< Prev||Next >|
The leader shows that style is no substitute for substance, that creating an impression is not more potent than acting from one's center.